

AD _____

Award Number: W81XWH-04-1-0102

TITLE: Structural and Functional Analysis of CA125: Potential for Early Diagnosis and Understanding the Immune Evasion Strategies of Epithelial Ovarian Tumors

PRINCIPAL INVESTIGATOR: Manish S. Patankar, Ph.D.

CONTRACTING ORGANIZATION: University of Wisconsin Madison
Madison, WI 53792

REPORT DATE: July 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-07-2005		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 JUL 2004 - 30 JUN 2005	
4. TITLE AND SUBTITLE Structural and Functional Analysis of CA125: Potential for Early Diagnosis and Understanding the Immune Evasion Strategies of Epithelial Ovarian Tumors				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0102	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Manish S. Patankar, Ph.D. E-Mail: patankar@wisc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Wisconsin Madison Madison, WI 53792				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT: The proposed studies will define the structure and the biological function of the epithelial ovarian tumor marker MUC16 (CA125). The knowledge obtained can be utilized to develop better diagnostic tests for early detection of ovarian cancer and also to understand the pathogenesis of this disease. Due to delays in procuring the appropriate approvals from the Institutional Review Boards we have not been able to initiate the proposed studies. We therefore do not have any major findings/accomplishments to report at this time.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	4	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	
SF 298.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	N/A
Reportable Outcomes.....	N/A
Conclusions.....	N/A
References.....	N/A
Supporting Documents.....	N/A
Appendices.....	N/A

INTRODUCTION: The major molecular marker for epithelial ovarian cancer is the antigen CA125. It is now known that CA125 is repeating peptide epitope that is expressed on the very large molecular weight mucin MUC16. The major goal of this project was to further understand the structure and biology of CA125 (hereafter referred to as MUC16) in order to enhance the capability of the serum CA125 test to detect epithelial ovarian cancer and also to understand the role of MUC16 in the pathogenesis of this malignancy. For this purpose we proposed to carefully analyze the oligosaccharides attached to MUC16 that was isolated from ovarian tumor cells *in vitro*, from the peritoneal fluid of ovarian cancer patients and from the amniotic fluid derived from pregnant women. Our hypothesis was that this analysis would help us distinguish between the different isoforms of the mucin. In the second and the third specific aims we proposed to study the role of MUC16 in inhibiting the innate (Natural killer; NK) cell and adaptive (T-cell) responses. The three specific aims of the proposal are listed below.

Specific Aim 1- Perform glycomic analysis of CA125 derived from cultured cells, ascites of EOC patients and human amniotic fluid.

Specific Aim 2- Determine if cell surface associated CA125 can protect OVCAR-3 cells from NK cell mediated cytolytic responses.

Specific Aim 3- Determine if CA125 can modulate the function of T cells.

BODY: We have not used any funds provided through this Department of Defense (DOD) grant. This was primarily because of the delay in acquiring the requisite approvals from the Institutional Review Boards of the PI's institution. We therefore do not have any major advances to report at this time.